CClinicalTrials.gg
CompletedNCT04769505SPIROMINDUpdated Mar 18, 2024

Mindfulness-based Interventions in COPD Patients

An interventional study of digital mindfulness-based intervention (MBI) in Chronic Obstructive Pulmonary Disease Exacerbation, sponsored by Karl Landsteiner Institute for Lung Research and Pneumological Oncology. Completed at 1 site in Austria. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Karl Landsteiner Institute for Lung Research and Pneumological Oncology · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The purpose of this pilot study is to assess the feasibility of a brief digital mindfulness-based intervention for COPD patients and its effectiveness regarding the reduction of psychological distress as well as stress.

Read the detailed description

Background:

Patients with chronic obstructive pulmonary disease (COPD) do not only suffer from somatic symptoms but also from symptoms of anxiety and depression (defined as psychological distress) as well as stress. As pharmacological interventions showed only limited effectiveness in targeting the latter, a need for additional treatment options emerges. In other chronic conditions, mindfulness-based interventions (MBIs) are effective in reducing symptoms of psychological distress and stress. Despite first promising results, research on MBIs in COPD patients is still scarce and mixed regarding their effects. Furthermore, it is crucial to implement mental health interventions adapted to the needs of COPD patients. Due to often experienced physical limitations and impaired mobility, digital MBIs seem particularly promising.

Aim and Research Questions:

Building on the above, this pilot randomized controlled trial aims to examine a) the feasibility of a brief digital MBI for COPD patients and b) its effects on psychological distress and stress.

Methods:

30 psychologically distressed (assessed by the Hospital Anxiety and Depression Scale, HADS-A ≥ 8 or HADS-D ≥ 8) COPD patients are screened for inclusion and exclusion criteria in a telephone interview and randomly assigned to the MBI (plus treatment as usual) or waitlist control group (treatment as usual). After a single face-to-face introductory session, patients in the MBI condition are instructed to conduct at least one of four brief audio-guided mindfulness exercises (10-15min) daily for 8 weeks, delivered on their smartphones. Following an ecological momentary approach, psychological and respiratory variables (e.g. subjective stress, dyspnoea) are assessed before and after each exercise. These data will be analysed using multilevel modelling. Moreover, primary (psychological distress) and secondary outcomes (e.g. chronic stress, fatigue) are measured at baseline, 4 weeks, 8 weeks, and follow-up, including questionnaires and assessments of biological stress markers (hair cortisol, heart rate variability, electrodermal activity). The data will be analysed using repeated measures ANOVAs. Finally, in semi-structured telephone exit interviews with 15 patients of the MBI group, the intervention's feasibility will be explored using a thematic analysis approach.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease Exacerbation
03

In context

Lung Diseases, Obstructive

2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.

This study's enrollment of 30 is below the median of 66 across 1,837 interventional studies indexed under Lung Diseases, Obstructive.

Browse Lung Diseases, Obstructive studies →

Lead sponsor

Karl Landsteiner Institute for Lung Research and Pneumological Oncology is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. spirometry confirmed (FEV1\<80%) COPD diagnosis
  2. psychological distress (as assessed by the Hospital Anxiety and Depression Scale): HADS-A ≥ 8 OR HADS-D ≥ 8 OR*
  3. age ≥ 40 years
  4. ability to understand German
  5. physical and mental capability to attend the intervention, judged by the treating physician
  6. life expectancy > 6 months as judged by treating physician
  7. ability to use a smartphone
  8. ability not to smoke for the duration of the measurement time points (2-3 hours) (This criterion has been added later, because we learned that this was a problem for some participants. However, smoking during the measurements heavily affects biomarker data and the subjective stress response to a stress induction protocol.)

Exclusion criteria

Exclusion Criteria:

  1. auditory impairment
  2. active asthma diagnosis ("Regardless of your COPD, have you had allergies and asthma in childhood or adolescence and needed medication for them at that time?" If no: No active asthma. If yes: "Is your asthma active and a problem now in addition to your COPD and do you currently need asthma medications because of it?" If no: No active asthma. If yes: exclusion)**
  3. any other known severe comorbidities such as heart failure (LVF\<35%), uncontrolled diabetes, concomitant cancer, stroke, unstable coronary heart disease, respiratory failure
  4. history of/current severe psychological disorder (e.g. schizophrenia, severe cognitive impairment)
  5. current acute exacerbation of COPD
  6. any other relevant acute health crisis interfering with the study intervention (e.g. Covid-19)
  7. receiving any psychosocial treatment (e.g. psychotherapy)
  8. regular other systematic mind-body-practice

(*) When the only exclusion criterion was the HADS, which was often the case, we contacted the participants two months later to screen them again and included them, if they were eligible.

(**) We further specified this criterion, as we learned that many patients were told to probably have asthma without them knowing exactly if they had an active asthma diagnosis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Intervention group

    Participants receive a digital mindfulness-based intervention (MBI) + treatment as usual.

    Behavioral: digital mindfulness-based intervention (MBI)

  • No intervention
    Wait list control group

    Participants receive treatment as usual during the intervention period. They are provided with the digital mindfulness-based intervention (MBI) after the intervention period. The waitlist control group receives the same intervention as the intervention group, with the exception of using not using the exercises via the software on the smartphone, but receiving the exercises as audio files.

Interventions

  • Behavioraldigital mindfulness-based intervention (MBI)

    The digital MBI consists of four auditory guided mindfulness exercises lasting between 10 and 15 minutes. The four exercises are a body scan and three sitting meditations (awareness of the heartbeat, awareness of the body, awareness of sounds). The exercises can be conducted via a software (https://www.movisens.com/de/produkte/movisensxs/) on participants' smartphones. Participants will be familiarized with the concept of mindfulness and the intervention in a single face-to-face introductory session. Additionally, participants will receive a manual, containing all relevant information. Participants will be instructed to practice at least once daily over the course of eight weeks. We recommended to come up with a fixed time point for the mindfulness practice to facilitate a routine. They can choose individually between the exercises. After the intervention period, participants received the exercises as audio files and could continue practicing.

06

What researchers measure

Primary outcomes

  1. Psychological distress

    Hospital Anxiety and Depression Scale (HADS; Zigmond \& Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression

    Time frame: baseline - 4 weeks

  2. Psychological distress

    Hospital Anxiety and Depression Scale (HADS; Zigmond \& Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement, interpreting both subscales for anxiety and depression

    Time frame: baseline - 8 weeks

  3. Patient's experiences with the digital MBI

    patients' experiences assessed in the exit interview (qualitative and quantitative data)

    Time frame: 8 weeks

Secondary outcomes

  1. Chronic stress

    assessed by Perceived Stress Scale (PSS-10; Cohen \& Williamson, 1988; German version Klein et al., 2016), scores 0-40, lower scores indicate improvement

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  2. Health related quality of life

    Chronic Respiratory Questionnaire (CRQ-SAS; German version Schünemann et al., 2003), scores: 20-140, higher scores indicate improvement

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  3. Health status impairment

    COPD Assessment Test (CAT; Jones et al., 2009), scores 0-40, lower scores indicate improvement

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  4. Fatigue

    Multidimensional Fatigue Inventory (MFI-20; German version Schwarz, Krauss, \& Hinz, 2003), scores 0-80, items have different polarity

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  5. Mindfulness

    Freiburger Mindfulness Inventory short form (FMI short form; Walach, Buchheld, Buttenmüller, Kleinknecht, \& Schmidt, 2006), scores 0-42, higher scores indicate improvement

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  6. Self-compassion

    Self-Compassion Scale short form (SCS short form; Raes, Pommier, Neff, \& Van Gucht, 2011; German version Hupfeld \& Ruffieux, 2011), scores 12-60, items have different polarity

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  7. Breathlessness catastrophizing

    Breathlessness Catastrophizing Scale (BCS; Solomon et al., 2015; German version adapted analogue to Pain Catastrophizing Scale Meyer, Sprott, \& Mannion, 2008), scores 0-52, lower scores indicate improvement

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  8. Stress reactivity

    the reactivity to stress assessed via examining heart rate variability (RMSSD) during the exposure to a mental stressor (stroop test)

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  9. Stress reactivity

    the reactivity to stress assessed via examining skin conductance level during the exposure to a mental stressor (stroop test)

    Time frame: baseline, 4 weeks, 8 weeks, 4 months, 6 months

  10. Hair cortisol

    concentration of hair cortisol (as biomarker for chronic stress)

    Time frame: baseline, 8 weeks, 4 months, 6 months

  11. Psychological distress

    Hospital Anxiety and Depression Scale (HADS; Zigmond \& Snaith, 1983; German version Herrmann-Lingen et al., 2011), scores: 0-42, lower scores indicate improvement

    Time frame: baseline, 4 months, 6 months

07

Study locations

1 site
  • Klinik Ottakring
    Vienna, 1160, Austria
08

References and documents

Study documents

  • Study protocol · Apr 26, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04769505
Lead sponsor
Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Collaborators
University of Vienna, Klinik Ottakring, Klinik Floridsdorf, Therme Wien Med (Ambulant Pulmonary Rehabilitation)
Responsible party
Georg-Christian Funk (Assoc.-Prof. Georg-Christian Funk, M.D., Karl Landsteiner Institute for Lung Research and Pneumological Oncology) — Principal investigator
First posted
Feb 24, 2021
Start date
Apr 1, 2021
Primary completion
Dec 5, 2022
Completion
Mar 27, 2023
Last update
Mar 18, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion